Figures & data
Table 1 Baseline data of all patients (n=64)
Table 2 DDGP regime-induced adverse reactions
Figure 1 PFS of 64 patients and OS of 55 patients after DDGP regime chemotherapy. (A) The 1-, 2- and 3-year PFS was 77.00%, 67.80% and 62.00%, respectively. (B) The 1-, 2- and 3-year OS was 81.50% 74.9% and 74.90%, respectively.
Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; OS, overall survival; PFS, progression-free survival.
![Figure 1 PFS of 64 patients and OS of 55 patients after DDGP regime chemotherapy. (A) The 1-, 2- and 3-year PFS was 77.00%, 67.80% and 62.00%, respectively. (B) The 1-, 2- and 3-year OS was 81.50% 74.9% and 74.90%, respectively.Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; OS, overall survival; PFS, progression-free survival.](/cms/asset/b660fc67-8721-4dca-a41f-7ebb4c0cfecd/dcmr_a_12186202_f0001_b.jpg)
Figure 2 Survival curves. (A) PFS is shown for all patients. No significant difference was noted in PFS between the EBV-DNA-positive group and EBV-DNA-negative group. (P=0.812). (B) OS is shown for 55 patients, the EBV-DNA-negative group has a better OS than EBV-DNA-positive group (P=0.046).
Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; EPV, Epstein-Barr virus; OS, overall survival; PFS, progression-free survival.
![Figure 2 Survival curves. (A) PFS is shown for all patients. No significant difference was noted in PFS between the EBV-DNA-positive group and EBV-DNA-negative group. (P=0.812). (B) OS is shown for 55 patients, the EBV-DNA-negative group has a better OS than EBV-DNA-positive group (P=0.046).Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; EPV, Epstein-Barr virus; OS, overall survival; PFS, progression-free survival.](/cms/asset/dcc5a294-99d2-44f4-a5d5-0d67d8bf8d7d/dcmr_a_12186202_f0002_b.jpg)
Figure 3 Comparison of PFS and OS curves between patients negative and positive for EBV in the EBV (+) group. (A) Progression-free survival (PFS) is shown for 28 patients negative for EBV (+) group, showing the turned to negative group has a better PFS than remained positive group (P=0.003). (B) OS is shown for 25 patients negative for EBV (+) group, showing the turned to negative group has a better OS than remained positive group (P=0.017).
Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; EPV, Epstein-Barr virus; OS, overall survival; PFS, progression-free survival.
![Figure 3 Comparison of PFS and OS curves between patients negative and positive for EBV in the EBV (+) group. (A) Progression-free survival (PFS) is shown for 28 patients negative for EBV (+) group, showing the turned to negative group has a better PFS than remained positive group (P=0.003). (B) OS is shown for 25 patients negative for EBV (+) group, showing the turned to negative group has a better OS than remained positive group (P=0.017).Abbreviations: DDGP, cisplatin, dexamethasone, gemcitabine and pegaspargase; EPV, Epstein-Barr virus; OS, overall survival; PFS, progression-free survival.](/cms/asset/95acf478-8ae6-49e2-a8bb-233b4216699e/dcmr_a_12186202_f0003_b.jpg)
Table 3 Comparison of pegaspargase- or L-asparaginase- or gemcitabine-based regimens in the treatment of extranodal NK/T-cell lymphoma